You are on page 1of 18

GUNA-TF GUNA-TF

The Homeopathic Use of Transfer factors

Physiological Therapy in chronic and recurrent infections

By Guna® S.p.a. Scientific Department © Copyright 2006 Guna® S.p.a.

GUNA-TF

WHAT ARE GUNA-TF? GUNA-TF?
GUNA-TF are Transfer Factors protein-based innovative homeopathic medicines at D7 (7 X for US Physicians) potency (10-7). The Transfer Factors are therapeutically active at a dosage of 100 ng/day; to obtain this specific concentration (corresponding to the amount of Transfer Factors that are contained in a Guna-TF capsule), the technique of homeopathic preparation has been used in order to realize a standard production according to current Good Manufacturing Practice. Transfer factors are short ribonucleopeptide chains with antigenic messenger RNA bases connected with short peptide chains composed of 6 or more amino acids. In simple words, they are tiny molecules providing for immune defence. They are all natural substances that work by “teaching” our own immune system to identify infectious agents that attack our body every day. Guna-TF are manufactured through a patented procedure by extracting them from lymph cells activated by specific antigens (viruses, yeasts, etc.). These Lymphoid lines are being cultivated in vitro and dialysed: in this way, the so-called DLE (Dialyzable Leukocyte Extract) can be containing over 200 molecules, weighting between 1.000 and 20.000 Dalton. Among these, there are Transfer Factors proteins responsible for the transfer of cell-mediated immunity.

GUNA-TF

GUNA-TF MECHANISM GUNA-TF OF ACTION
One of the most common theories on the mechanism of action of Transfer Factors is that they are part of the receptor lying on the Th lymphocyte surface in a steric position that is necessary to identify the specific antigenic agent. Administering Transfer Factors proteins means activating the mechanisms of receptor re-synthesization (specific receptors of a specific antigen) by Th lymphocytes, thus enhancing their receptor capacity and hence their immune effectiveness. Transfer Factors are also capable of activating intracell mechanisms responsible for the production of cytokines, which are important intracell communication messengers between different immune response intermediates. In particular, they activate the synthesis of pro-inflammatory interleukins (for instance IL1, IL6, TNF, INF, etc) which are essential to induce an effective physiological response towards a pathogen agent.

COMPLEMENT FACTORS

GUNA-TF

FOR WHICH DISEASES CAN GUNA-TF BE USED? GUNA-TF
The chronicization and recurrence of an infectious disease represent the most evident sign that the Immune System has been attacked by pathogen agents. Transfer Factors struggle against the body non-response by providing it with the necessary factors to help the Immune System face the antigen attack. Guna-TF treatment is capable of transferring the immune pathway of the donor of Transfer Factors to the patient to be treated to trigger an autologous response that has to be sufficient and suitable to fight the antigenic attack in a physiological way. The treatment with Guna-TF is suitable in the forms of cell-mediated immune selected deficit. The response is specific only toward the antigen codifying the Transfer Factor:

• Herpes simplex type 1 and 2 • Monilia albicans • HPV

· Guna-TF Herpes · Guna-TF Candida · Guna-TF Papilloma

Transfactor: Key notes

¬100 ng/die = quantity of Transfer Factors proteins that are therapeutically ¬Transfactor = Transfer of cell-mediated immunity ¬Transfactor = Antigen-specific immunotherapy ¬
active and correspond to the quantity of TF D7 (7 X for US Physicians) in a capsule of Guna-TF

GUNA-TF GUNA-TF

¬ Transfactor = Physiological treatment of chronic recurrent
infections diseases ¬ Transfactor = Effective and risk-free treatment

HOW TO USE GUNA-TF:
• Guna-TF are in capsules for oral use. • Standard dosage: 1 capsule/day for 5 continuous days (for instance: from Monday to Friday, excluding Saturday and Sunday) for 3-4 months without break.

PACKAGE SIZE
Bottle of 20 x 230 mg capsules.

GUNA-TF HERPES

GUNA-TF HERPES GUNA-TF HERPES

Composition

Transfer Factors-HSV type 1 and 2 at D7 potency (7X for US Physicians).

Indications

Herpes labialis and Herpes genitalis recurrent infections; herpetic keratoconjunctivitis; herpetic-like cutaneous infections.

Dosage

1 capsule/day for 5 continuous days (for instance: from Monday to Friday, excluding Saturday and Sunday) for 3-4 months without break.

Package size

Bottle of 20 x 230 mg capsules.

Combination with other Guna medicines:

·

Strengthening of immune defenses in Herpes simplex I and II infections:

Guna-TF Herpes + Guna-Virus

Clinical case
Prevention of recurrent labial and genital herpes infections
A clinical research study has been carried out on 44 patients, 22 affected by labial herpes and 22 affected by genital herpes. All the patients have been treated for 6 continuous months with a Transfer Factor preparation obtained from in vitro culture extract of specific HSV 1 and 2 from dyalized bovine lymphocytes. In the monitoring period before the treatment (the 44 patients have been monitored globally 26.660 days long) there have been 544 reacutizations with a 61.2 Relapse Index. The monitoring period during and after treatment has been of 16.945 days for the 44 patients. In this period there have been 121 reacutizations with a 21.4 Relapse Index.
From Pizza G, Viza V, De Vinci C, Palareti AP, Cuzzocrea DE, Fornarola V & Baricordi OR. “Orally administered HSV-specific transfer factor (TF) prevents genital and/or labial herpes relapses”. Biotherapy, Vol. 9:62-72, 1996.

GUNA-TF CANDIDA

GUNA-TF CANDIDA GUNA-TF CANDIDA

Composition

Transfer Factor Monilia albicans at D7 potency (7X for US Physicians).

Indications

Recurrent Candida infections; mucocutaneous yeast problems in different body areas; dermatitis.

Dosage

1 capsule/day for 5 continuous days (for instance from Monday to Friday, excluding Saturday and Sunday) for 3-4 months without break.

Package size

Bottle of 20 x 230 mg capsules.

Combination with other Guna medicines:

·

Acute and chronic Vulvo-vaginites as a consequence of yeast problems

(Candidiasis): Guna-TF Candida + MycoxTM + CitomixTM (20 drops three times/day for 1 month)

·

Dysbiotic Candidiasis: Guna-TF Candida + EubioflorTM+ CitomixTM

(20 drops three times/day for 2 months)

Clinical case
Guna-TF-Candida in chronic mucocutaneous Candidiasis
A clinical research study has been carried out on 15 patients (3 M; 12 F) affected by Chronic Mucocutaneous Candidiasis (6 patients with oral Candidiasis and 9 patients with Vaginal Candidiasis). The patients have been treated with a Transfer Factor preparation from in vitro culture extract of Monilia albicans. The CMI (Cell-Mediated Immunity) has been considered through the Leukocyte Migration Test (LMT) and the Lymphocyte Stimulation Test (LST) with the presence of Candidiasis lysate before, during and after treatment. 83.9% of LMTS Test were positive during treatment, showing an increased incidence of Candidiasis antigen reactivity. In the monitoring period improvements of the health condition have been recorded.

From Masi M., De Vinci C., Baricordi O.R. “Transfer Factor in chronic mucocutaneous candidiasis”. Biotherapy. 9(1-3)97-103, 1996.

GUNA-TF PAPILLOMA

GUNA-TF PAPILLOMA GUNA-TF PAPILLOMA

Composition

Transfer Factor Papillomavirus at D7(7 X for US Physicians) potency.

Indications

Recurrent Papillomavirus infections; condylomatoses; post-surgical condyloma treatment; warts.

Dosage

1 capsule/day for 5 continous days (for instance from Monday to Friday, excluding Saturday and Sunday) for 3-4 months without break.

Package size

Bottle of 20 x 230 mg capsules.

Combination with other Guna medicines:

·

Strengthening of immune defenses in Human Papilloma Virus (HPV)

infections: Guna-TF Papilloma + CitomixTM

Clinical case
Use of TF-Papilloma in HPV disease
A clinical research study has been carried out on 160 patients, both male and female, affected by HPV (Papilomavirus) lesions or PAP test or biopsy positive to koilocytosis to consider the results of a treatment with Transfer Factor preparation from in vitro culture HPV extract to prevent relapses. The protocol provided for the use of one capsule/day for 5 continuous days/week for 8 weeks and then one capsule/day for 3 days/week (on alternate days) for another 4 weeks. The viral HPV lesions have almost disappeared in the patients treated. In 97% of the cases where the electrosurgical treatment has been used in conjunction with the preparation no further persistent symptoms of disease have been recorded.

From M. Destro Castaniti. “L'utilizzo del Transfactor 11 nella patologia virale da HPV (casistica di 160 casi)”. La Medicina Biologica, 2000/4; 95-100.

GUNA-TF

Literature references
1. Blume M.R., Rosenbaum E.H., Cohen R.J., Gerhow J, Glassberg AB, Shepley E. Adjuvant immunotherapy of high risk stage I melanoma with transfer factor. Cancer, 47, 882-888, 1981. 2. Borden E.C. - Augmented tumour-associated antigen expression by interferons. JNCI, 80, 148-149, 1988. 3. Bukowski R.M., Deodhar S., Hewlett J.S., Greenstreet R. - Randomized controlled trial of transfer factor in stage II malignant melanoma. Cancer 51, 269-272, 1983. 4. Conti F., Orlandini A. - Trattamento di manifestazioni allergiche con Transfer Factor (TF). La Medicina Biologica, 1998/3; pp. 35-39. 5. Corrado F., Pizza G., De Vinci C., Corrado G., Mannini D., Maver P., Ferri C., Aiello E. - L'impiego del transfer factor nel carcinoma prostatico metastatizzato. In Atti del Convegno Internazionale sul Cancro della Prostata. Garofalo F, Tomaselli V Eds. Monduzzi Editore, Bologna. p. 89-92, 1988. 6. Corrado F., Pizza G., De Vinci C., Corrado G. - Il trattamento con transfer factor delle metastasi ossee da adenocarcinoma della prostata. In: Le Metastasi, Atti XII Cong Naz Oncol, Saccani F, Becchi G, Carretti D, Maltoni C Ed, Monduzzi Editore, Bologna, 1233-1235, 1986. 7. Corrado F., Pizza G. - Tentativas de inmunoterapia en los tumores del aparato urinario. Arch Esp Urol, 37, 659-666, 1984. 8. Destro Castaniti M. - L'utilizzo del Transfactor 11 nella patologia virale da HPV (casistica di 160 casi) - La Medicina Biologica 2000/4, pagg. 95-100. 9. Fudenberg H.H., Fudenberg H.H. - Transfer Factor: Past, present and future. Annu Rev Pharmacol Toxicol, 29: 475-516, 1989. 10. Fudenberg H.H., Smith C.L. - Immunomodulation and immunotherapy: an overview of biologic and synthetic agents and their effects on the human immune system. EOS Riv. Immunol Immunopharmacol, 1: 3-11, 1981. 11. Fudenberg H.H., Wilson G.B. et al - Dialyzable Leucocyte Extracts (Transfer Factor): A review of clinical results and immunological methods for donor selection, evaluation of activities and patient monitoring. In: Thymus, Thymic Hormones and T Lymphocytes. Eds: Aiuti F, Wigzell H. Proc Serono Symp, Academic Press, London, 38: 391-421, 1980. 12. Fudenberg H.H., Wilson G.B., Tsang K.Y. - Evaluation of transfer cator potency and prediction of clinical response. In: Immunomodulation: New Frontiers and Advances. Eds: Fudenberg H.H., Whitten H., Ambrogi F. Plenum Press, New York, pp.115130, 1984. 13. Fusjisawa T., Yamaguchi Y., Kimura H. et al - Adjuvant immunotherapy of primary resected lung cancer with transfer factor. Cancer, 54, 663-669, 1984. 14. Gonzalez R.L., Wong P., Spitler L.E. - Adjuvant immunotherapy with Transfer Factor in patients with melanoma metastatic to lung. Cancer, 45, 57-63, 1980. 15. Greiner J.W., Fisher P.B., Pestka S., Schlom J.: Differential effects of recombinant human leukocyte interferon on cell surface antigen expression. Cancer Res, 46, 4984-4990, 1986. 16. Huo B. - Clinical application of Transfer Factor in China.ibidem pp. 451-459. 17. Jones J.F., Minnich L.L., Jeter W.-S., Pritchett, Fulginiti V.A., Wedgwood R.J. - treatment of childood combined Epstein-Barr virus/cyto-

megalovirus infection with oral bovine transfer factor. Lancet 2: 122-124, 1981. 18. Jones J.F., Pizza G., De Vinci C. - Infectious mononucleosis: immunotherapy with EBVspecific Transfer Factor? J Exp Pathol, 3(4), 399-406, 1987. 19. Kirkpatrick C.H. - Transfer Factor - Perspective in human and veterinary medicine. J Exp Pathol, vol 3(4), 383-398, 1987. 20. Lawrence H.S. - Proc. Soc. Exp. Biol Med 71, 516, 1949. 21. Malzac J. - Applicazioni terapeutiche dei Transfer-factors nella prassi clinica quotidiana: prime esperienze e risultati clinici - La Medicina Biologica 1997/2 Supplemento, pagg. 50-54. 22. Malzac J. - Transfer Factor, specifica attivazione della memoria del linfocita - La Medicina Biologica 1996/2 Supplemento, pagg. 4650. 23. Mazzella G., Ronchi M., Villanova N., Mohamed A.A., Pizza G., De Vinci C., Viza D., Roda E., Barbara L. - Treatment of chronic B virus hepatitis with specific Transfer Factor. J Exp Pathol, 3, 421-423, 1987. 24. Meduri R., Campos E., Scorolli L., De Vinci C., Pizza G., Vizà D. - Efficacia del Transfer Factor nel trattamento di pazienti con infezioni erpetiche oculari ricorrenti. In: “Biotherapy” 9/1996. 25. Neequaye J., Viza D., Pizza G., Levine P.H., De Vinci C. et al - Specific Transfer Factor with activity against Epstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma. Anticancer Res, 10,: 1183-1188, 1990. 26. Nkrumah F.K., Pizza G., Neequaye J., Viza D., De Vinci C., Levine P.H. - Transfer Factor in prevention of Burkitt's Lymphoma relapses. J Exp Pathol, 3, 463-469, 1987. 27. Orlandini A. - Il Transfer Factor: la proteina

responsabile del trasferimento della reattività cellulo mediata verso antigeni specifici - La Medicina Biologica 1996/2; pagg. 37-42. 28. Paddock G.V., Wilson G.B., Lin F.K., O'Leary, Fudenberg H.H. - In: Electrophoresis '81, Eds: Allen R, Arnaud P. Edited by De Gruyter, NY, pp. 479-486, 1981. 29. Pizza G., Viza D., Ablashi D.V., Faggioni A., Armstrong G., Levine P.H., De Vinci C., Innocenti R. - Transfer of reactivity with in vitro produced Transfer Factor in Rhesus and Owl monkeys. Lymphokine Res, 4, 351-357, 1985. 30. Pross HF, Baines M. - Studies of human natural killer cells. I. In vivo parameters affecting normal cytotoxic function. Int J Cancer, 29, 383-390, 1982. 31. Roda E., Pizza G., Viza D., Mastroroberto L., De Vinci C., Barbara L.: Transfer Factor for the treatment of HBsAg positive chronic active hepatitis. Proc Soc Biol Med (Usa), 178, 405-410, 1985. 32. Sasakawa S., Takenouchi K., Masumoto C., Mura T., Saito S et al: Clinical trials of dialyzable leukocyte extract (RCTF-I) in Japan. In: Leukocyte Dialyzates and Transfer Factor, Eds Mayer V, Borvak, pp.141-145. Inst Virol, Slovak Acad Sci, 1987. 33. Schwartz R.S., Jeter W.S. - Oral-administration of human dializable transfer factor in a patient with psoriasis. Arch Dermatol, 117: 3-4, 1981. 34. Viza D., Rosenfeld F., Phillips J., Vich J.M., Denis, Bonissent J.F., Dogbe K. - Specific bovine transfer factor for the treatment of herpes infections. In: Immunobiology of Transfer Factor, Kirkpatrick CH, Burger DR, Lawrence HS Eds, Ac Press, NY, 245-259, 1983. 35. Viza D. - Transfer Factor: un immunomodulatore nella lotta contro le malattie infettive -

Literature references
La Medicina Biologica 2000/4, pagg. 31-37. 36. Viza D., Orlandini A. - Il Transfer Factor specifico (TF 11) nel trattamento delle affezioni muco-cutanee da Papillomavirus (HPV) - La Medicina Biologica 1999/3, pagg. 1115. 37. Whyte R.I., Schork A., Sloan H., Orringer M.B., Kirsh M.M. - Adjuvant treatment using for bronchogenic carcinoma: longterm follow-up. Ann Thorac Surg 53, 3916, 1992. 38. Wilson G.B., Fudenberg H.H. - Is controversy about “transfer factor therapy” near the end? Immunol Today. 4: 157-161, 1983. 39. Wilson G.B., Jonsson H.T., Halushka P.V., Garner B.P., Berkaw M.N. - Contribution of prostaglandins to the biological activity of Dyalizable Leukocytes Extracts containing Transfer Factor. Ibidem, pp.137-150. 40. Wilson G.B., Metcalf J.F. jr., Fudenberg H.H. - Treatment of Mycobacterium fortuitum pulmonary infection with Transfer Factor: New methodology for evaluating TF potency and predicting clinical response. Clin Immunol Immunopathol, 23, 478491, 1982. 41. Wilson G.B., Paddock G.V., Fudenberg H.H.: Bovine “Transfer Factor”: an oligoribonucleopeptide wich initiates antigen-specific lymphocyte responsiveness. Thymus, 4: 335-350, 1982. 42. Wilson G.B., Paddock G.V., Fudenberg H.H.: Effect of dialyzable leukocyte extracts with transfer factor activity on leukocytes migration in vitro. V. Antigen-specific lymphocyte responsiveness can be iniated by two structurally distinct polyribonucleotides. Thymus 2: 257-276, 1981.

Contact Us
For USA customers GUNA Incorporated 1520 Tramway Blvd. NE, STE, 150 Albuquerque, New Mexico 87112, USA 1-888-GUNA-TEL (486-2835) 1-888-GUNA-FAX (486-2329) Contact your Medical Sales Consultant directly at: 505-217-3977 or fax to 505-217-3996 Please give us your opinion and feedback by emailing us at info@gunainc.com For all other countries outside the United States Please email us at export@guna.it

GUNA-TF
GUNA S.p.a. Via Palmanova, 71 – 20132 MILANO Tel. 02.28018.1 – Fax 02.2822234 Internet: www.guna.it – e-mail: info@guna.it
Cod.: 7GN046 Stampa: 12/2005 DOCUMENTAZIONE SCIENTIFICA RISERVATA ALLA CLASSE MEDICA